Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Fallopian tube secretory epithelial cells (FTSECs) are likely the main precursor cell type of high-grade serous ovarian cancers (HGSOCs), but these tumors may also arise from ovarian surface epithelial cells (OSECs). We profiled global landscapes of gene expression and active chromatin to characterize molecular similarities between OSECs (n = 114), FTSECs (n = 74), and HGSOCs (n = 394). A one-class machine learning algorithm predicts that most HGSOCs derive from FTSECs, with particularly high FTSEC scores in mesenchymal-type HGSOCs (p < 8 × 10). However, a subset of HGSOCs likely derive from OSECs, particularly HGSOCs of the proliferative type (p < 2 × 10), suggesting a dualistic model for HGSOC origins. Super-enhancer (SE) landscapes were also more similar between FTSECs and HGSOCs than between OSECs and HGSOCs (p < 2.2 × 10). The SOX18 transcription factor (TF) coincided with a HGSOC-specific SE, and ectopic overexpression of SOX18 in FTSECs caused epithelial-to-mesenchymal transition, indicating that SOX18 plays a role in establishing the mesenchymal signature of fallopian-derived HGSOCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.celrep.2019.10.122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of MHC Class I Molecules (HLA-A, -B, -C, -E, -F, -G, and -J) Decreases From Early to Late Stage in Ovarian Cancer.
Am J Reprod Immunol
September 2025
Department of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, Tokat, Türkiye.
Problem: Interferon-ε (IFNε), which is highly abundant in the epithelium of the female reproductive tract (FRT), is a recently identified tumor suppressor for ovarian cancer. IFNε induces the expression of certain HLA class I family members in HGSOC (high-grade serous ovarian cancer), and its expression is lost during ovarian tumorigenesis. However, tumor stage-dependent expression of HLA class I family members in ovarian cancer has not been previously studied.
View Article and Find Full Text PDFMulti-task deep learning for automatic image segmentation and treatment response assessment in metastatic ovarian cancer.
Int J Comput Assist Radiol Surg
September 2025
Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Purpose: : High-grade serous ovarian carcinoma (HGSOC) is characterised by significant spatial and temporal heterogeneity, often presenting at an advanced metastatic stage. One of the most common treatment approaches involves neoadjuvant chemotherapy (NACT), followed by surgery. However, the multi-scale complexity of HGSOC poses a major challenge in evaluating response to NACT.
View Article and Find Full Text PDFA new generation of N-heterocyclic carbene (NHC) gold-selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models.
Chem Sci
August 2025
Department of Chemistry and Centre for Sustainable Chemistry, Ghent University Ghent Belgium
Two distinct synthetic pathways are disclosed that lead to new gold-selenolato complexes, stabilized by N-heterocyclic carbenes (NHCs). The weak base route can provide facile access to phenylselenolate complexes of gold, using both NHC and phopshine ligands. In addition, the pathway based on the carbometallation of elemental selenium enables the construction of a more diverse library of products, based on substituted aryl-selenide fragments whose selenol congeners are not commercially available.
View Article and Find Full Text PDFDoes BRCA Mutation Status Influence Ovarian Cancer Onset Timing and Patients' Treatment Outcomes?
Genes (Basel)
July 2025
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
Background/objectives: Mutations in the and genes are well-known risk factors for ovarian cancer. They are also associated with response to platinum-based chemotherapy; however, their definitive impact on patient prognosis remains not fully understood. This study aimed to investigate the influence of mutation status on the age of ovarian cancer onset and on treatment outcomes in patients with high-grade serous ovarian cancer.
View Article and Find Full Text PDFHomologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment.
Curr Issues Mol Biol
August 2025
Department of Pathology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19121, USA.
Homologous recombination deficiency (HRD) is a pivotal biomarker in precision oncology, driving therapeutic strategies for ovarian and breast cancers through impaired DNA double-strand break repair. This narrative review synthesizes recent advances (2021-2025) in HRD's biological basis, prevalence, detection methods, and clinical implications, focusing on high-grade serous ovarian carcinoma (HGSOC; ~50% HRD prevalence) and triple-negative breast cancer (TNBC; 50-70% prevalence). HRD arises from genetic (, , ) and epigenetic alterations (e.
View Article and Find Full Text PDF